BridgeBio Pharma, Inc. (BBIO) Free cash flow
- Free cash flow · 12 months (USD): Value $-435.39M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -61.06%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-435.39M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-434.37M − $1.01M ≈ $-435.39M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -61.06% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-435.39M ÷ $713.07M × 100 ≈ -61.06% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-434.37M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | (m) | Operating cash flow / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -434.37M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 1.01M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -435.39M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 713.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | (m) | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-435.39M | (m) | $-434.37M | $1.01M | (m) | $713.07M | (m) | (m) | (m) | (m) | -61.06% | (m) |
| 2026-03-31 | $-445.12M | (m) | $-443.95M | $1.17M | (m) | $579.96M | (m) | (m) | (m) | (m) | -76.75% | (m) |
| 2025-12-31 | $-447.01M | (m) | $-445.91M | $1.10M | (m) | $502.08M | (m) | (m) | (m) | (m) | -89.03% | (m) |
| 2025-09-30 | $-585.93M | (m) | $-584.82M | $1.11M | (m) | $353.78M | (m) | (m) | (m) | (m) | -165.62% | (m) |
| 2025-06-30 | $-656.59M | (m) | $-655.81M | $778.00K | (m) | $235.81M | (m) | (m) | (m) | (m) | -278.44% | (m) |
| 2025-03-31 | $-500.66M | (m) | $-500.42M | $238.00K | (m) | $127.42M | (m) | (m) | (m) | (m) | -392.94% | (m) |
| 2024-12-31 | $-521.66M | (m) | $-520.73M | $933.00K | (m) | $221.90M | (m) | (m) | (m) | (m) | -235.09% | (m) |
| 2024-09-30 | $-451.54M | (m) | $-450.22M | $1.32M | (m) | $217.76M | (m) | (m) | (m) | (m) | -207.35% | (m) |
| 2024-06-30 | $-416.49M | (m) | $-414.88M | $1.61M | (m) | $219.12M | (m) | (m) | (m) | (m) | -190.07% | (m) |
| 2024-03-31 | $-604.92M | (m) | $-602.93M | $1.99M | (m) | $218.60M | (m) | (m) | (m) | (m) | -276.73% | (m) |
| 2023-12-31 | $-529.03M | (m) | $-527.72M | $1.31M | (m) | $9.30M | (m) | (m) | (m) | (m) | -5686.62% | (m) |
| 2023-09-30 | $-497.82M | (m) | $-496.14M | $1.67M | (m) | $9.43M | (m) | (m) | (m) | (m) | -5280.19% | (m) |
| 2023-06-30 | $-488.08M | (m) | $-486.08M | $2.00M | (m) | $5.67M | (m) | (m) | (m) | (m) | -8600.55% | (m) |
| 2023-03-31 | $-407.15M | (m) | $-403.18M | $3.97M | (m) | $77.78M | (m) | (m) | (m) | (m) | -523.47% | (m) |
| 2022-12-31 | $-424.31M | (m) | $-419.49M | $4.82M | (m) | $77.65M | (m) | (m) | (m) | (m) | -546.46% | (m) |
| 2022-09-30 | $-466.70M | (m) | $-460.15M | $6.56M | (m) | $88.66M | (m) | (m) | (m) | (m) | -526.37% | (m) |
| 2022-06-30 | $-458.80M | (m) | $-446.54M | $12.26M | (m) | $90.67M | (m) | (m) | (m) | (m) | -506.01% | (m) |
| 2022-03-31 | $-519.95M | (m) | $-507.80M | $12.14M | (m) | $70.95M | (m) | (m) | (m) | (m) | -732.86% | (m) |
| 2021-12-31 | $-511.18M | (m) | $-497.93M | $13.25M | (m) | $69.72M | (m) | (m) | (m) | (m) | -733.23% | (m) |
| 2021-09-30 | $-473.16M | (m) | $-460.30M | $12.86M | (m) | $56.95M | (m) | (m) | (m) | (m) | -830.80% | (m) |
| 2021-06-30 | $-477.37M | (m) | $-470.42M | $6.94M | (m) | $62.73M | (m) | (m) | (m) | (m) | -760.92% | (m) |
| 2021-03-31 | $-471.56M | (m) | $-466.56M | $5.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-407.23M | (m) | $-399.71M | $7.52M | (m) | $8.25M | (m) | (m) | (m) | (m) | -4936.74% | (m) |
| 2020-09-30 | $-386.77M | (m) | $-379.66M | $7.12M | (m) | $21.95M | (m) | (m) | (m) | (m) | -1762.39% | (m) |
| 2020-06-30 | $-304.92M | (m) | $-297.97M | $6.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-285.06M | (m) | $-278.37M | $6.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-256.23M | (m) | $-253.59M | $2.64M | (m) | $40.56M | (m) | (m) | (m) | (m) | -631.72% | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-138.82M | (m) | $-136.64M | $2.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-40.95M | (m) | $-40.49M | $464.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |